IO Therapies in the Advanced Bladder Cancer Clinic: Aligning Your Team for Success
Please Note: Credit Is No Longer Available
As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs. Neal Shore, Arjun Balar, Lidia Lopez, and Nurse Joanie Pfahl as they examine the new paradigm of bladder treatment using ICIs, and discuss the important role of each person on the treatment team.
Consider the evolving roles of ICIs in multimodal and/or combination regimens, including use earlier in the disease course in BCG-unresponsive disease.
This activity is presented by Creative Educational Concepts and Bladder Cancer Advocacy Network and supported by independent educational grants from AstraZeneca and Genentech.
To complete the other activities in this series please click here.
Urology community physicians, physician assistants, nurse practitioners, nurses, and pharmacists.
- Consider the evolving roles of ICIs in multimodal and/or combination regimens, including use earlier in the disease course in BCG-unresponsive disease.
- Incorporate available patient education for immunotherapies used in UBC, including education on immune-related adverse events and role of the interprofessional bladder cancer team.
Neal Shore, MD, FACS (Activity Chair)
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina
Arjun V. Balar, MD
Director, Genitourinary Medical Oncology Program
NYU Langone Perlmutter Cancer Center
New York, New York
Lidia Lopez, APN-C
UCLA GU Oncology NP
Division of Medicine, Hematology/Oncology
Los Angeles, CA
Joanie Pfahl, RN
Atlantic Urology Clinics
Myrtle Beach, South Carolina
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Susan H. Gitzinger, PharmD, MPA–has no financial relationships to disclose in relation to this activity.
Kirollos S. Hanna, PharmD, BCPS, BCOP–has disclosed that he is a consultant for Seattle Genetics and is a member of the speakers' bureau for Astellas, Bristol-Myers Squibb, and Seattle Genetics.
Neal Shore, MD, FACS–has disclosed that he is a consultant and receives grant/research support from Abbvie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Color Genomics, Dendreon, Ferring, Genentech, Genomic Health, Genzyme, Innovia, Invitae, Janssen, Merck, Myriad, Nymox, Panacea, Pfizer, Roche, Sanofi, and Tolmar.
Arjun V. Balar, MD–has disclosed that he is a consultant for AstraZeneca/Medimmune, Genentech, Immunomedics, Incyte, Janssen, Merck, Nektar, Pfizer, and Seattle Genetics. He receives grant/research support from AstraZeneca/Medimmune (institution), Genentech (institution), Immunomedics (institution), Merck (institution), Nektar, and Seattle Genetics (institution). He is a member of the Speakers' Bureau for AstraZeneca/Medimmune, Genentech, and Merck. He has equity and is a Scientific Advisory Board Member for EpiVax Oncology. He is also on the Steering/Scientific Advisory Committee for Merck and Nektar.
Lidia Lopez, APN-C–has disclosed she is a consultant for Pfizer.
Joanie Pfahl–has no financial relationships to disclose in relation to this activity.
Bishoy Morris Faltas, MD–has no financial relationships to disclose in relation to this activity.
Sami Larson, PharmD–has no financial relationships to disclose in relation to this activity.
Caroline Pratz, CRNP–has no financial relationships to disclose in relation to this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-021-H01-P).
This activity is designated for 1.0 contact hour.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® NABP® CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation